Contact
searchSearch
HMP Global
Login

Hodgkin Lymphoma

News
Exclusion of Involved-Node Radiotherapy Among ePET-Negative Vs ePET-Positive Patients With Localized Hodgkin Lymphoma
01/17/2024
Jordan Kadish
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up...
01/17/2024
Oncology
From Oncology
News
Treatment Strategies for Advanced Classic Hodgkin Lymphoma
07/08/2022
Ellen Kurek
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies...
07/08/2022
Journal of Clinical Pathways
Stephen Ansell, MD, PhD
Interview
First-Line Brentuximab Vedotin Plus Chemotherapy Improves OS in Classical Hodgkin Lymphoma
06/14/2022
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD,...
06/14/2022
Journal of Clinical Pathways
Videos
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
01/14/2021
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD,...
01/14/2021
Journal of Clinical Pathways
FDA Alerts
FDA Expands Approval of Pembrolizumab for Classical Hodgkin Lymphoma
10/15/2020
The FDA expanded the approval of pembrolizumab to include adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL or cHL that has relapsed after 2 or more lines of therapy.
The FDA expanded the approval of pembrolizumab to include adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL or cHL that has relapsed after 2 or more lines of therapy.
The FDA expanded the approval of...
10/15/2020
Journal of Clinical Pathways
News
Reducing Cause-Specific Mortality in Classical Hodgkin Lymphoma
10/14/2020
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early...
10/14/2020
Journal of Clinical Pathways
News
Assessing Frequency of Secondary Malignancies in Survivors of Hodgkin Lymphoma
06/17/2020
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study...
06/17/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of Monotherapies for Relapsed, Refractory Hodgkin Lymphoma
05/14/2020
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or...
05/14/2020
Journal of Clinical Pathways

Expert Insights

Stephen Ansell, MD, PhD
Interview
First-Line Brentuximab Vedotin Plus Chemotherapy Improves OS in Classical Hodgkin Lymphoma
06/14/2022
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, plus dacarbazine treatment resulted in a statistically significant reduction in the risk of death when...
Stephen Ansell, MD, PhD,...
06/14/2022
Journal of Clinical Pathways
Videos
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
01/14/2021
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD,...
01/14/2021
Journal of Clinical Pathways
Nikki Martin Headshot
Interview
Adopting Reflex Biomarker Testing to Improve Clinical Workflows for Patients With Non–Small Cell Lung Cancer
09/18/2026
Nikki Martin, MA
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin,...
09/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part II
08/18/2026
Kelsey Pan, MD
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses...
08/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part I
08/18/2026
Kelsey Pan, MD
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan,...
08/18/2026
Journal of Clinical Pathways
Deirdre Saulet, PhD
Blog
How AI, Data, and Real-World Evidence Are Transforming Oncology Clinical Pathways
07/14/2026
Deirdre Saulet, PhD
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026...
07/14/2026
Journal of Clinical Pathways
B-cell lymphoma
Videos
Dual-Targeting CAR T-Cell Therapy: Implications for Relapsed or Refractory Large B-Cell Lymphoma
07/06/2026
Paolo Strati, MD
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how...
07/06/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis: Part 2
06/19/2026
Rahul Mudumba, PhD, MHS
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how...
06/19/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis
06/18/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how...
06/18/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration: Part 2
06/17/2026
Kishen Patel, PharmD
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores...
06/17/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration
06/17/2026
Kishen Patel, PharmD
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel,...
06/17/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Interview
Cardiopulmonary Comorbidities and CRS Risk After CAR T-Cell Therapy in DLBCL: Insights From Real-World Data
06/11/2026
Heidi Cho, MD
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that...
06/11/2026
Journal of Clinical Pathways

Newsfeed

News
Exclusion of Involved-Node Radiotherapy Among ePET-Negative Vs ePET-Positive Patients With Localized Hodgkin Lymphoma
01/17/2024
Jordan Kadish
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up...
01/17/2024
Oncology
News
Treatment Strategies for Advanced Classic Hodgkin Lymphoma
07/08/2022
Ellen Kurek
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies...
07/08/2022
Journal of Clinical Pathways
News
Reducing Cause-Specific Mortality in Classical Hodgkin Lymphoma
10/14/2020
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early...
10/14/2020
Journal of Clinical Pathways
News
Assessing Frequency of Secondary Malignancies in Survivors of Hodgkin Lymphoma
06/17/2020
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study...
06/17/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of Monotherapies for Relapsed, Refractory Hodgkin Lymphoma
05/14/2020
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or...
05/14/2020
Journal of Clinical Pathways
News
Anemia Associated With Higher Mortality and AML Transformation Risk in Myelofibrosis
09/17/2026
Rebecca Amrick
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the...
09/17/2026
Journal of Clinical Pathways
News
Enhanced Financial Assistance Associated With Improved Radiotherapy Completion
09/08/2026
Rebecca Amrick
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing...
09/08/2026
Journal of Clinical Pathways
News
Molecular Testing Improves Survival Outcomes for Patients With Endometrial Cancer, Study Finds
09/03/2026
Rebecca Amrick
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing...
09/03/2026
Journal of Clinical Pathways
News
Rituximab Biosimilars Demonstrate Clinical Efficiency and Significant Cost Savings Among Patients With NHL and CLL
08/31/2026
Rebecca Amrick
Researchers found that rituximab biosimilars were associated with similar health outcomes and lower care costs than originator rituximab when used to treat patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Researchers found that rituximab biosimilars were associated with similar health outcomes and lower care costs than originator rituximab when used to treat patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Researchers found that rituximab...
08/31/2026
Journal of Clinical Pathways
News
Initiation of Bispecific Antibodies Associated With High Care Costs for Patients With MM
08/24/2026
Rebecca Amrick
A study found that longer hospitalizations were associated with higher care costs among patients with MM initiating treatment with bispecific antibodies, raising concerns about care delivery and access.
A study found that longer hospitalizations were associated with higher care costs among patients with MM initiating treatment with bispecific antibodies, raising concerns about care delivery and access.
A study found that longer...
08/24/2026
Journal of Clinical Pathways
News
Cytopenia Associated With Worse Survival Outcomes in Patients With Myelofibrosis
08/17/2026
Rebecca Amrick
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence...
08/17/2026
Journal of Clinical Pathways
News
The Impact of Interventions on Serious Illness Conversations
08/14/2026
Rebecca Amrick
Researchers found that intervention strategies focused on clinician reminders could increase rates of serious illness conversations among patients with projected poor health outcomes.
Researchers found that intervention strategies focused on clinician reminders could increase rates of serious illness conversations among patients with projected poor health outcomes.
Researchers found that...
08/14/2026
Journal of Clinical Pathways
News
The Current Treatment Landscape for Myelofibrosis
08/10/2026
Rebecca Amrick
Researchers provided a comprehensive overview of the main treatment options for myelofibrosis (MF), including the primary Janus kinase (JAK) inhibitors, potential combination strategies, and non-pharmacologic interventions used in disease...
Researchers provided a comprehensive overview of the main treatment options for myelofibrosis (MF), including the primary Janus kinase (JAK) inhibitors, potential combination strategies, and non-pharmacologic interventions used in disease...
Researchers provided a...
08/10/2026
Journal of Clinical Pathways
News
Financial Navigation Not Associated With Reduced Financial Hardship
08/03/2026
Rebecca Amrick
A study found no association between financial navigation and improvements in financial hardship or quality of life among patients with cancer, highlighting the need for future research on strategies that could reduce cancer-related financial...
A study found no association between financial navigation and improvements in financial hardship or quality of life among patients with cancer, highlighting the need for future research on strategies that could reduce cancer-related financial...
A study found no association...
08/03/2026
Journal of Clinical Pathways
News
High-Risk Features Impact Patient Survival in Relapsed or Refractory MM
07/27/2026
Rebecca Amrick
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk features such as extramedullary disease, plasma cell leukemia, and focal lesions were associated with poor survival outcomes among patients with relapsed or refractory multiple myeloma (MM).
A study found that high-risk...
07/27/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use